Characterization of the microvascular cerebral blood flow response to obstructive apneic events during night sleep by Zirak, Peyman et al.
Characterization of the microvascular cerebral blood1
flow response to obstructive apneic events during night2
sleep3
Peyman Ziraka,†, Clara Gregori-Plaa,*, Igor Blancoa, Ana Fortunab,4
Gianluca Cottaa, Pau Bramona, Isabel Serrac, Anna Molab, Jordi5
Solà-Solerd,e,f, Beatriz F. Giraldo-Giraldod,e,f, Turgut Durdurana,g, and6
Mercedes Mayosb,h7
aICFO-Institut de Ciències Fotòniques, The Barcelona Institute of Science8
and Technology, Av. Carl Friedrich Gauss, 3, Castelldefels (Barcelona),9
08860, Spain.10
bSleep Unit. Department of Respiratory Medicine, Hospital de la Santa11
Creu i Sant Pau, C. de Sant Quintí, 89, 08041, Barcelona, Spain.12
cCentre de Recerca Matemàtica (CRM), 08193, Bellaterra, Spain.13
dDepartment of Automatic Control (ESAII), Universitat Politècnica de14
Catalunya (UPC)-Barcelona Tech, 08028, Barcelona, Spain15
eInstitute for Bioengineering of Catalonia (IBEC), The Barcelona Institute16
of Science and Technology, 08019, Barcelona, Spain17
1
fCentro de Investigación Biomédica en Red de Bioingeniería, Biomateriales18
y Nanomedicina (CIBER-BBN), Zaragoza, 50018, Spain19
gInstitució Catalana de Recerca i Estudis Avançats (ICREA), Passeig de20
Lluís Companys, 23, 08010, Barcelona, Spain.21
hCIBER Enfermedades Respiratorias (CibeRes) (CB06/06), C. Montforte22
de Lemos 3-5, 28029, Madrid, Spain.23
†now at Department of Chemistry and Center for Applied Photonics (CAP),24
University of Konstanz, Universitätsstr. 10, 78457, Konstanz, Germany.25
*Clara Gregori-Pla: clara.gregori@icfo.eu26
2
Abstract27
Obstructive apnea causes periodic changes in cerebral and systemic hemodynamics, which28
may contribute to the increased risk of cerebrovascular disease of patients with obstructive29
sleep apnea (OSA) syndrome. The improved understanding of the consequences of an apneic30
event on the brain perfusion may improve our knowledge of these consequences and then31
allow for the development of preventive strategies. Our aim was to characterize the typical32
microvascular, cortical cerebral blood flow (CBF) changes in an OSA population during an33
apneic event.34
Sixteen patients (age 58 ± 8 years, 75% male) with a high risk of severe OSA were35
measured with a polysomnography device and with di use correlation spectroscopy (DCS)36
during one night of sleep with 1365 obstructive apneic events detected. All patients were37
later confirmed to su er from severe OSA syndrome with a mean of 83 ± 15 apneas and38
hypopneas per hour.39
DCS has been shown to be able to characterize the microvascular CBF
:::::::::
response
:::
to
:::::
each40
:::::
event
::::::
with
::
a
::::::::::
su cient
::::::::::::::::::
contrast-to-noise
::::::
ratio
:::
to
:::::::
reveal
::::
its
:::::::::::
dynamics.
::
It has also revealed41
that an apnea causes a peak increase of microvascular CBF (30 ± 17 %) at the end of the42
event followed by a drop (-20 ± 12 %) similar to what was observed in macrovascular CBF43
velocity of the middle cerebral artery. This study paves the way for the utilization of DCS44
for further studies on these populations.45
Keywords: sleep disorder breathing, cerebral blood flow, brain perfusion, di use correla-46
tion spectroscopy.47
1 Introduction48
Obstructive sleep apnea (OSA) is characterized by the intermittent and repetitive collapse49
of the upper airway during sleep with simultaneous respiratory e ort. Symptoms such as50
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headache, sleepiness, fatigue, depression and di culties on keeping concentration are fre-51
quent in patients with OSA [1]. Even more, obstructive sleep apnea has been related to an52
increased risk of cardiovascular and cerebrovascular diseases such as systemic hypertension,53
atrial fibrillation and cerebral stroke [2, 3, 4, 5], as well as to increased mortality [6, 7]. The54
key factors involved are the repetitive intermittent hypoxia, the increased sympathetic ac-55
tivity, the sleep fragmentation, and the periodic cerebral hemodynamic changes but further56
understanding is desirable [8, 9].57
Previously, the apnea-induced changes of cerebral hemodynamics have been studied and58
characterized by several groups through the measurement of the cerebral blood flow velocity59
(CBFV) in the middle cerebral artery by transcranial Doppler (TCD) [10, 11, 12, 13, 14]. In60
Bålfors et al. [10] study, both CBFV and the mean arterial blood pressure showed a biphasic61
pattern where during the apnea a gradual increase of both CBFV and mean arterial blood62
pressure were observed followed by a sudden drop after the end of the apneic event. These63
hemodynamic changes are rapid and, therefore, many modalities for CBF measurement64
are not applicable, limiting the literature to studies where the macrovascular CBFV was65
measured by TCD. Few studies have also used microvascular cerebral blood oxygenation66
measured by near-infrared di use optical spectroscopy (NIRS-DOS) as a surrogate [15, 16,67
17, 18].68
However, neither TCD nor NIRS-DOS can measure the actual microvascular cerebral69
blood flow (CBF) in the brain, which is a desirable parameter since it provides direct infor-70
mation about the health of the brain [19], acts as biomarker of cerebral autoregulation [20],71
and is a key parameter to measure the oxygen metabolism [21, 22, 23]. This is what led us to72
adopt a new emerging technology, di use correlation spectroscopy (DCS), to measure local,73
microvascular CBF on the brain cortex non-invasively at the bed-side [24, 25]. DCS utilizes74
near-infrared light like NIRS-DOS but relies on the speckle statistics of the laser light to75
characterize red blood cell motion. To the best of our knowledge, only one study attempted76
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to measure night sleep changes by DCS in OSA patients [26] but could not characterize77
individual apneic events, presumably due to technical limitations.78
In this study, we have used a DCS device to evaluate and characterize the individual79
apnea-induced hemodynamic changes of cerebral blood flow measured continuously in pa-80
tients with severe OSA simultaneously by using DCS and polysomnography.81
2 Methods82
This study was conducted at a referral Sleep Unit (Department of Respiratory Medicine,83
Hospital de la Santa Creu i Sant Pau) in Barcelona, Spain. The study protocol was approved84
by the local ethical committee (EC/11/001/1166). All participants gave their informed85
written consent. It was part of a larger study involving other modalities.86
Patients were referred to a sleep study at the unit because of being at a high risk of severe87
OSA according to the Epworth sleeping scale [27] results, other clinical symptoms and the88
results of a previous home-use nocturnal pulse oximetry session [28].89
Those who were older than 80 years, had previous or current continuous positive air pres-90
sure (CPAP) treatment [29], had chronic obstructive pulmonary or neuromuscular diseases,91
a previous ischemic stroke, or who refused to participate in the study were excluded. De-92
mographic and clinical characteristics were obtained for all participants. A pre-established93
questionnaire was used to collect demographic variables including their medical history, car-94
diovascular risk factors and current medications. Diagnosis of arterial hypertension (AHT)95
was defined as having Ø140 mmHg systolic blood pressure and/or Ø90 mmHg diastolic blood96
pressure [30].97
All patients were asked to arrive at the Sleep Unit at 19:00 on the study date. They98
were instructed to avoid ca einated or alcoholic beverages twenty-four hours previously to99
the measurement. Polysomnography (PSG) monitors and optical probes were placed as100
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explained below. Concurrent optical and PSG data were acquired during the night sleep.101
If the obstructive apnea or hypopnea index (AHI; number of apneas and hypopneas per102
hour of sleep) was greater than 30 after about four hours of sleep, the clinical technician103
fixed a CPAP mouth-nose mask to find the correct air pressure for preventing apneas (called104
split-night PSG). For those patients with split-night PSG, only the data recording of the105
first four hours of night sleep without CPAP was then used for further analysis since there106
are practically no apneas during CPAP use.107
2.1 Overnight polysomnography108
Polysomnography (Siesta Compumedics, Melbourne, Australia) sensors were wirelessly con-109
nected to the monitoring room. Amongst other variables, PSG included the recording of the110
oronasal flow (by a thermistor and a nasal cannula), the thoracic and abdominal movements111
(by a respiratory inductance plethysmography band), the heart rate (HR; by electrography112
chest leads and calculated from the electrocardiogram as described in [31]) and the arterial113
oxygen saturation (SpO2; by pulse oximetry).114
PSG data was post-processed and manually scored by the sleep technicians according115
to the Spanish Sleep group recommendations [29], which, among other things, describe the116
rules for scoring respiratory events. Sleep technicians determined the start and end time117
points of each apneic event, identified the apnea types (i.e. obstructive apnea, hypopnea,118
mixed apnea, and central apnea) and calculated, among other parameters, the percentage of119
total sleep time with SpO2 lower than 90% (CT90), the four per cent oxygen desaturation120
index (ODI4) and the AHI. From these variables, the diagnosis of OSA and the high degree121
of severity of these patients were confirmed or rejected after our recruitment. Due to the122
di erent pathophysiology of each type of apneic event, and for simplicity, only obstructive123
apneas were used for the analysis of this study.124
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2.2 Determination of the cerebral blood flow by di use correla-125
tion spectroscopy126
Microvascular CBF during the whole night sleep was continuously assessed by a custom-127
built DCS system that was previously described [25, 32, 33]. Briefly, the DCS consisted of128
a mode-hope free, long-coherence-length, continuous-wave laser at 785 nm and eight single129
photon avalanche photodiode detectors whose outputs were fed to a custom-built hardware130
autocorrelator. DCS uses the intensity autocorrelation of the di use light to evaluate the131
motion of the scatterers, i.e. the red blood cells [24]. The intensity autocorrelation data132
is then fitted by a physical model of the photon di usion in tissues to determine a blood133
flow index (BFI), which is recorded as a continuous variable. The BFI (cm2/sec) is not a134
measure of absolute blood flow in traditional units. Even though under controlled situations135
the absolute values are proportional to the absolute blood flow [34], the relative changes are136
more reliable and have been shown to be quantitative [35, 25]. Therefore, we report relative137
changes in this work.138
The averaging time of the DCS measurement in each patient was adjusted from one to139
three seconds during the first minutes of the measurement in order to maximize the signal-140
to-noise ratio for the rest of the sleep measurement. In order to co-register the DCS data141
with the PSG variables, a transistor-transistor logic signal was generated through a digital142
output channel, which was fed into the PSG device and was used as a marker to synchronize143
DCS and all PSG variables.144
The optical probe was made of custom built, ninety-degree bent fibers of 2 mm of external145
diameter and consisted of a source fiber of a core of 200 µm and a detector fiber bundle of146
four single-mode fibers of a core of 5.6 µm. The source-detector separation was 2.5 cm. We147
have assumed that the hemodynamic changes in the brain are homogeneous bilaterally and,148
for patient comfort, we opted to fix a single DCS probe on the right forehead of the patient.149
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The probe was placed over the patient’s forehead, properly fixed to avoid the movement150
of the patient, and allowed the placement and removal of the CPAP mask when necessary151
with the minimum impact possible on the optical measurement. A black elastic band was152
attached to the standard CPAP head frame to fix the optical probe and the CPAP mask on153
the head.154
2.3 Group and individual analysis of apnea induced cerebral blood155
flow, heart rate and arterial oxygen saturation changes156
Individual apneic events were characterized by the percent relative CBF change ( rCBF),157
defined as  rCBF = ( BFIBFIbl ≠ 1)◊ 100 where BFIbl is the average of the cerebral BFI from158
thirty seconds before the apnea start up to thirty seconds after the apnea end. This choice for159
BFIbl was used to account for the possible changes in the absolute CBF at di erent stages of160
sleep and to correct for slight changes in the probe position during the whole night of sleep.161
We note that we have taken a similar approach to systemic variables too, i.e.  rHR was162
defined as  rHR = ( HRHRbl ≠ 1)◊ 100, and  SpO2 was defined as  SpO2 = SpO2 ≠ SpO2bl.163
In order to discard the CBF, HR and SpO2 responses to obstructive apneic events with164
a low signal quality or with movement artifacts during the measurement, all responses were165
studied by previously developed methods for outlier detection [36, 37]. These allowed us to166
find the responses that exhibited a di erent time behavior or that presented higher or lower167
magnitude values than the majority. Also, the outlier detection method [36, 37] allowed168
us to reduce the e ect of outliers that exist not only due to measurement issues but also169
because of uncontrolled physiological outliers (e. g. mixture of two events, other physiological170
alterations). Each variable (CBF, HR or SpO2) was analyzed independently. For instance, if171
the  rCBF response for one apnea was classified as an outlier, it did not imply that  rHR172
and/or  SpO2 response for the same apnea were also classified as outliers. We do not expect173
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this to cause any errors in the data analysis due to the large number of events that were174
analyzed. The outlier detection procedure was implemented in R [38] using the “fda.usc”175
[37] package and the R function “Outliergram” [36].176
After removing the outliers from our database, all the remaining apneic events for each177
variable ( rCBF,  rHR or  SpO2) of all patients were averaged in order to visualize rep-178
resentative cerebral and systemic dynamics of obstructive apneas. The averaging was per-179
formed by 1) selecting the start and the end of each apnea based on PSG measurements180
using the established criteria (see above), 2) calculating the  rCBF,  rHR or  SpO2 traces181
for each apnea as explained previously, 3) aligning the data considering as the pivot point182
the start of each individual apnea, as shown in Figure 1-a and 4) grouping and averaging183
all apneas within a given range of apnea duration. Four groups were used based on their184
duration; apneas shorter than or equal to 15 seconds, apneas longer than 15 and up-to 30185
seconds, apneas longer than 30 and up-to 45 seconds, and apneas longer than 45 and up-to186
60 seconds. There were apneas of varying lengths in each group and, if an apnea was shorter187
than the full duration, it did not contribute to the remaining average. This grouping before188
averaging was done since the apnea lengths vary from ten seconds up to around a minute189
and, even though it is not perfect, grouping by duration allowed us to see more details of190
the dynamics.191
This heterogeneity of the duration of apneas did not allow us to analyze the full du-192
ration of the single apnea induced  rCBF,  rHR or  SpO2 changes. Instead, we have193
considered the apnea end as a pivot point to calculate each parameter. The parameters194
associated to each obstructive apneic event were considered as a function dependent on time195
( rCBF(time),  rHR(time) and  SpO2(time)), and then, the relative extrema of these196
functions along a specific time interval relative to the apnea end were calculated. The posi-197
tive extrema are referenced as “peak” values, and the negative as “drop” values. The time198
windows to find these extrema were from -5 to 15 seconds for the first extremum on  rCBF199
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(see Figure 1-b as an example), from 0 to 15 seconds for the  rHR, and from 5 to 35 seconds200
for the  SpO2. In order to visualize the possible link between the hypoxemia present in201
these patients and the cerebral blood flow, also the second extremum that was outside this202
window was considered for  rCBF. These time windows were selected from the literature203
[10, 39] and also by visual observation of all the apneas plotted together from -30 seconds204
to 60 seconds in order to include the majority of the peak/drop values. This analysis was205
performed with Matlab 2012a (Mathworks, MA, USA).206
The association between the calculated  rCBF ,  rHR and  SpO2 extrema to the207
apnea duration (from the PSG) was analyzed by adjusting a linear mixed-e ect model [40].208
The patient identifier was used as a random factor, the parameter apnea duration was209
the fixed e ect and the positive and negative extrema (previously defined as “peaks” and210
“drops”) of the apnea time response on variables  rCBF ,  rHR and  SpO2 were the211
predictors. The linear mixed-e ect analysis was carried out in the R programming language212
and environment [40] using the “nlme” package. The associations between the mean of the213
previously calculated  rCBF,  rHR and  SpO2 extrema responses for each patient with214
gender, age and body mass index (one by one) were analyzed by performing simple linear215
models. The demographic parameters were the fixed e ects and the mean calculated extrema216
were the predictors. The residuals of the models were checked for linearity by plotting the217
standard residuals versus the predicted means. Residuals were inspected for deviations from218
homoscedasticity. Also, residuals were inspected for deviations from normality by means of219
histograms and also by means of Q-Q plots. The presence of influential data points was also220
inspected.221
The Wilcoxon signed-rank test was used to check if  rCBF,  rHR and  SpO2 peaks222
and drops for each grouping of apneas by duration were di erent from zero.223
A p-value <0.05 was considered to be statistically significant.224
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3 Results225
We have included sixteen patients with high risk of severe OSA. Fourteen patients were226
studied with a split-night PSG and two patients with overnight PSG. All sixteen patients227
were diagnosed with severe OSA according to the criteria described above.228
The microvascular CBF during the whole night of sleep was continuously assessed by DCS229
with a range of 0.9 to 3.1 (1.5 ± 0.5, mean ± standard deviation) second time-resolution230
in order to maximize the signal-to-noise ratio. The time-resolution was decided during a231
baseline test as mentioned in methods. The typical count rate for these patients was from232
50 to 150 kHz.233
A total of 3817 apneic events were identified including 1365 (36%) obstructive apneic234
events. The DCS recording in two patients was discarded (14% of total obstructive apneic235
events) due to synchronization failure between the PSG and the DCS. Part of the HR236
of di erent patients was discarded due to low ECG data quality recording (15% of total237
obstructive apneic events). The SpO2 recording in one patient was discarded (9% of total238
obstructive apneic events) due to the detachment of the pulse oximeter during the main part239
of the recording. After removing the outliers, 87% obstructive apneic events were considered240
for the CBF, 90% events for the HR, and 88% events for the SpO2. Further clarification of241
the total of number of apneas considered for the analysis is given in Appendix.242
Table 1 shows the demographic, clinical and polysomnographic characteristics of the243
subjects. The table shows that this is a relatively homogeneous group of patients with a244
very severe obstructive sleep apnea syndrome, commonly associated with a high percentage245
of cardiovascular and metabolic comorbidity. The severity of OSA syndrome in our cohort246
is shown by an AHI higher than 30, and high values of CT90 and ODI4. The prevalence of247
hypertension in our sample was 62.3% which is consistent with the results of other studies248
[41]. Four patients received beta blockers, which may cause alterations in the heart rate [42].249
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Table 1: Demographic, clinical and polysomnographic characteristics of the patient popula-
tion. Values are reported in median (interquartile range) or frequency (%). OSA, obstructive
sleep apnea; BMI, body mass index; AHT, arterial hypertension; AHI, apnea-hypopnea in-
dex; SpO2, arterial oxygen saturation by pulse oximetry; CT90, % of time SpO2 lower than
90% of total sleep time; ODI4, 4% oxygen desaturation index.
OSA patients (n=16)
Age (years) 57 (52-64.5)
Males n (%) 12 (75)
BMI (kg/cm2) 34 (32-37.5)
Epworth 9.5 (7.5-15.5)
AHT n (%) 10 (62.5)
Smokers n (%) 13 (81)
Diabetes n (%) 5 (31.25)
Dyslipidemia n (%) 3 (18.75)
AHI (n./hours) 85 (76-94)
Mean SpO2 (%) 92 (90.5-93.5)
CT90 (%) 23 (12-33)
ODI4 (%) 74 (65-85)
Total number of apneas detected by polysomnography n 3817
Obstructive apneas n (%) 1365 (36)
Hypopneas n (%) 1918 (50)
Mixed apneas n (%) 358 (9)
Central apneas n (%) 176 (5)
There was no other relevant use of medications.250
As an example of the apnea e ect on systemic variables and cerebral blood flow, Figure251
2 shows three minutes of continuous BFI measurement together with nasal airflow, HR and252
SpO2 changes for one representative patient. BFI has been plotted here instead of  rCBF,253
since this is calculated from a specific baseline of each individual apnea where the baseline254
corresponds to a pre-apnea period of thirty seconds from the start up-to a post-apnea period255
up-to thirty seconds from the end. From the PSG recording, we can see that SpO2 shows256
a drop with a delay relative to the apneic event. In this time period with frequent apneas,257
characteristic of patients with severe OSA, the SpO2 drop of the previous apnea is in the258
apnea period of the next event. It can also be observed that the HR starts to rise when the259
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breathing restarts after a period of cessation. BFI also shows a similar behavior as the HR.260
To better understand the general response of CBF to obstructive apneic events,  rCBF261
measurements during obstructive apneas were grouped depending on their duration (as ex-262
plained in the methods section) and averaged as shown in Figure 4. It can be observed that263
the mean of the di erent apnea-duration groups follows a similar pattern: a  rCBF increase264
towards the apnea end followed by a drop (in  rCBF).265
Apnea duration range from 15 up-to 30 seconds has been chosen for further visualization266
of the data since it has the highest number of events. The peak observed in CBF in Figure267
4 is also observed in the HR in Figure 5, whereas the SpO2 shows a drop. We can also268
observe in Figure 2 that cerebral and systemic variables are not constant during pre-apnea269
periods. This e ect is clearly evident in the peaks/drops right before or at the start of the270
apnea in Figure 4 and Figure 5. This is attributed to the presence of a previous apneic event271
equal or less than thirty seconds prior to the start of the evaluated event, which was the272
case for 80% (n=3054) of all the events detected by PSG, i.e. the subject’s physiology did273
not yet stabilize. According to this, and following the literature, in order to characterize the274
response to a given apnea, we have considered only the CBF peaks/drops, HR peaks, and275
SpO2 drops near the end of the apnea or in the post-apnea period (as explained in methods276
section).277
Figure 3 and Table 2 show the individual data points and average amounts of peaks/drops278
for cerebral and systemic variables ( rCBF,  rHR and  SpO2) grouped by apnea duration.279
All  rCBF,  rHR and  SpO2 peaks and drops for each grouping of apneas by duration280
were statistically di erent from zero. Microvascular CBF increased by a mean of 30 ± 17 %281
at the end of the event followed by a drop of -20 ± 12 %. HR, as expected, increased by -11282
± 7 %. Also, SpO2, as expected, decreased by -13 ± 4 %.283
When fitting a linear model with the  rCBF peak or the  rHR peak as the dependent284
parameter and the apnea duration as the predictor parameter, positive statistically signifi-285
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Table 2: Mean ± standard deviation values for the amount of the peak or drop close to the
apnea end for the di erent apneas grouped by their duration and for all apneas.  rCBF,
relative cerebral blood flow;  rHR, relative heart rate;  SpO2, arterial oxygen saturation
change by pulse oximetry.
 rCBF  rHR  SpO2
Apnea
duration
(sec)
n (%) Peak (%) Drop (%) n (%) Peak (%) n (%) Drop (%)
Æ15 130 (13) 22±15 -19±16 116 (11) 8±5 126 (11) -4±2
>15 to Æ30 618 (62) 29±18 -20±13 681 (65) 11±6 697 (64) -6±4
>30 to Æ45 238 (24) 35±15 -21±7 236 (23) 13±8 258 (24) -9±6
>45 to Æ60 16 (1) 45±20 -22±9 7 (1) 19±8 7 (1) -13±4
All, 24±8 1002 (100) 30±17 -20±12 1040 (100) 11±7 1088 (100) -6±4
cant associations (—=0.5 and —=0.4, respectively) were found (p<0.001) for both dependent286
parameters. When the dependent parameter was the  rCBF drop or the  SpO2 drop,287
negative statistically significant associations (—=-0.2 and —=-0.2, respectively) were found288
(p<0.001) for both dependent parameters. Females, in comparison to males, showed a larger289
CBF response (—=9.9, p=0.040). Older age was associated to smaller a SpO2 response (—=-290
0.2, p=0.004). No statistically significant associations were found with the body mass index291
(p>0.05).292
4 Discussion293
In this work, we have demonstrated the successful assessment of microvascular CBF during294
individual obstructive apneic events by non-invasive, continuous DCS measurements. All295
subjects tolerated the study during the whole-night sleep showing the suitability of the tech-296
nique for bed-side continuous CBF monitoring over long time periods and its compatibility297
with standard PSG monitoring.298
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Our first finding was that DCS results had
::::
the su cient contrast-to-noise ratio
::
in
::::::
order299
::
to
:
enable us to measure the dynamics of microvascular CBF during obstructive apneic events300
in a synchronized manner with systemic variables as illustrated in Figure 2. HR and SpO2301
followed the expected dynamics according to the literature [15, 16, 39, 43]. CBF showed302
a similar behavior as HR. There is only one study that has also measured microvascular303
CBF in OSA patients continuously with di use correlation spectroscopy (DCS) [26] during304
night sleep. However, apnea cerebral hemodynamics were not characterized, instead, only305
two-minute time periods with apneas and two-minute time periods with no apneas were306
compared in order to see altered variability of the microvascular hemodynamics with or307
without apneas.308
Our second finding revealed a steep rise and a peak of microvascular  rCBF towards309
or after the end of an apnea, followed by a drop. Figure 5 indicates that the  rCBF310
and  rHR traces are similar and are in-phase. This could suggest that we are primarily311
measuring the extracerebral contributions instead of the cerebral contribution, since, in312
principle, cerebral signals are not directly driven by heart-rate changes, i.e. the cerebral313
signals are auto-regulated. However, the literature supports this type of correlation between314
heart-rate changes and the cerebral signals during an apnea. For example, the reported315
microvascular CBF changes measured by DCS follow the same patterns of those of middle316
cerebral artery CBFV measured by TCD [10, 13, 14] showing a peak close to the end of the317
apnea. In addition to the similarity of their temporal profile, these  rCBF and CBFV peaks318
:::
are
:::
in
:::::::::::
agreement
::::::::
within
:::::::::::
variability
:::
of
::::
the
:::::
both
:::::::::::
methods.
:
The 14.6 ± 14 % peak change in319
CBFV right after the apnea end by Bålfors et al. [10] is similar to our microvascular  rCBF320
values of 30 ± 17 % for obstructive apnea as it can be seen in Table 2. Also Alex et al.321
[13] found similar peaks in CBFV of 22% to 42%. However, other authors have reported322
larger CBFV peaks. Klingelhöfer et al. [11] found changes of CBFV of 19-219% and Siebler323
et al. [14] found a mean CBFV peak during apnea of 142% compared with the baseline324
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CBFV. The di erences of these last studies with our results may be related to the longer325
apnea durations and to di erent normalization of the data. The  rCBF drops after the326
apnea end are also in agreement with the CBFV drops found in the bibliography [10, 11].327
These results tell us that there is a decrease in cerebral perfusion due to an apneic event. If328
these intermittent decreases lead to ischemia, they can cause hypoxic/ischemic brain injury,329
especially if cerebrovascular reactivity and regulation are impaired [44].330
Another point about the extracerebral contamination is that DCS in adult brain with331
this source-detector separation has been validated against other measures of CBF in di erent332
studies where it was demonstrated that the relative changes in di erent challenges follow the333
intra-cerebral signals closely [45, 46, 25, 47].334
However, despite these arguments, we cannot rule out the possibility that microvascular335
and macrovascular changes diverge and that extracerebral signals have strongly impressed336
themselves on the DCS signals. Future studies are needed to study this point.337
We have observed (Figure 2 and Figure 4) that cerebral hemodynamics in the pre- and338
during-apnea periods are not stable as it has been previously observed due to the influence of339
the previous apnea [15, 16, 39, 43]. 80% (n=3054) of the total events (i.e. obstructive apneas,340
mixed apneas, hypopneas and central apneas) are followed by the next episode within 30341
seconds or less, hence, we expect that the e ects of the previous events overlap with the342
next apnea. This is because the rapid succession of events do not allow ample time for the343
physiology to recover as observed by Bålfors et al. [10] where they have reported that it344
took up to 60 seconds for CBFV to return to baseline after the apnea termination.345
We have attempted to resolve this by isolating apneas by forcing di erent lengths of346
minimum gaps between the events, however, in this group of patients with a severe condition,347
due to the high frequency of repetitive events, only a small group of apneas could be isolated348
(as shown in Figure 6) and no final conclusions could be drawn about what would have349
happened if there had been no overlapping apneas.350
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The CBF peak and drop amplitudes that are characteristic of each apneic event were351
associated with the apnea duration. The association of the peak with the apnea duration352
has also been observed previously for CBFV in the middle cerebral artery [13]. About353
the systemic variables, a correlation of desaturation depth with apnea duration has been354
observed previously by several authors [48, 49]. Also, the abrupt HR increase immediately355
after obstructive apnoeas has been documented [50], and recently, in a preliminary work, we356
have already observed a correlation between HR excursion and the duration of apneas [31].357
These results tell us that the longer the apnea duration, the bigger is its e ect on systemic358
variables, but also, on the microvascular cerebral hemodynamics.359
About the gender e ect that was observed where females showed larger CBF responses,360
this is in contrast to Edlow et al. [51] who has reported a smaller CBF response to HOB361
manipulation for females in the healthy population. It is di cult to know whether this is362
due to a smaller head circumference and a smaller scalp-to-brain-distance hence a smaller363
extracerebral e ect or not. We also note that we did not observe a body mass index e ect.364
However, Peppard et al. [52] observed an association between body mass index and SpO2365
decreases. The body mass index was quite homogeneous for our group (32-37.5) which may366
have hidden this relationship. About the age e ect that was observed, older age has already367
been associated to smaller apnea SpO2 responses as predicted in the literature [53].368
Finally, we have discarded several apneas (13% for CBF, 10% for HR and 12% for SpO2;369
see Appendix) as outliers. Similar percentages of apneas were removed between CBF and370
the PSG variables (HR and SpO2) and, therefore, these support the idea that the DCS signal371
has the quality needed in the clinics.372
Our study has some potential limitations that should be taken in consideration. First,373
the contribution from the extracerebral tissues could not be assessed independently since our374
probe lacked a short source-detector separation. A multidistance source-detector separation375
probe and pressure modulation algorithms [54] should be considered in future studies. We376
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do note that a source-detector separation of 2.5 cm has been found to be a good compromise377
and was validated in numerous studies [25, 47, 46]. Second, the absorption and reduced378
scattering coe cients have been considered as constant along the study. While significant379
changes in the reduced scattering coe cient can a ect the DCS results, they are not expected380
during an apnea. The changes in the absorption coe cient due to an apnea have a minimal381
e ect on the DCS signal [24, 47]. Third, there are additional factors to consider to go deeper382
into the physiology of the relationship between the systemic physiology and microvascular383
CBF changes such as the e ects of di erents sleep states, arousals, leg movement and others384
sleep events. The detailed analysis is beyond the scope of this paper and will be a point385
of future studies. Finally, our findings correspond to a group of patients with very severe386
OSA which implies that these results are not necessarily extrapolated to the di erent OSA387
severities. However, at the same time, it strengthens the validity of our results for patients388
with severe OSA.389
In summary, we have demonstrated that DCS is a suitable technology for bed-side and390
continuous monitoring of the microvascular  rCBF during sleep. We were able to ob-391
tain su cient signal-to-noise ratio
::
to
:::::::
reveal
::::
the
::::::::::
dynamics
:::::
and
::::
the
:::::::::::
canonical
:::::::
shape
:::
of
::::
the392
::::::::::::::
microvascular
:::::::::
cerebral
::::::
blood
:::::
flow
:::::::::
changes.
:
We were then also able to characterize each cere-393
bral blood flow peak and the following drop in each obstructive sleep apneic event, as well394
as to visualize the apnea induced cerebral and systemic hemodynamics simultaneously in395
patients with severe obstructive sleep apnea. This work, to our best knowledge, is the first396
characterization of the microvascular cerebral blood flow during an obstructive sleep apnea.397
Appendix398
Not all the apneic events detected by the polysomnography technique have been used for399
the data plotting and analysis. Table 3 shows the di erent steps from the initial number of400
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Table 3: Total number of apneas considered from the polysomnography detection and the
apneas considered for the analysis for di erent steps. The total number of events remaining
after each step and its percentage (%) are reported. Step 1, total events detected by PSG.
Step 2, obstructive apneic events detected by PSG. Step 3, obstructive apneic events detected
by PSG and recorded by each technique. Step 4, obstructive apneic events detected by PSG
and recorded with each technique after removing the outliers. CBF, cerebral blood flow; HR,
heart rate; SpO2, arterial oxygen saturation by pulse oximetry; PSG, polysomonography.
Step CBF HR SpO2
1 Total apneas detected by PSG, n (%) 3817 (100) 3817 (100) 3817 (100)
2 Obstructive apneas detected by PSG, n (%) of step 1 1365 (36) 1365 (36) 1365 (36)
3 Obstructive apneas, n (%) of step 2 1150 (84) 1161 (85) 1239 (91)
4 Obstructive apneas after outlier removal, n (%) of step 3 1002 (87) 1040 (90) 1088 (88)
apneas detected by the PSG to the final number of apneas considered.401
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Figure 1: a) Visualization of the averaging of the di erent apneas grouped by their duration.
These apneas from the same duration range will be averaged for obtaining a canonical apnea
shape. b) Characterization of individual apneas, where the apnea end is considered as a
pivot point. The light gray region indicates the apneic event. The dark gray region indicates
the time window used to find the first extremum value. The first and second extrema are
labeled.
Figure 2: a) Nasal airflow, b) heart rate, c) arterial oxygen saturation, and d) cerebral blood
flow index dynamics during three minutes of night sleep for one representative subject. The
gray regions between two vertical lines indicate the obstructive apneic events.
Figure 3: a) Cerebral blood flow ( rCBF), b) heart rate ( rHR) and c) arterial oxygen sat-
uration ( SpO2) peaks and/or drops are shown, divided in di erent apnea group durations
and for all apneas. These are also summarized in Table 2. (ú) indicates that the group is
statistically di erent from zero with p<0.001. (†) indicates that the group is statistically
di erent from zero with p<0.05.
Figure 4: Mean cerebral blood flow changes ( rCBF) during obstructive apneic events for
apnea durations of: a) 10 up-to 15 seconds; b) 15 up-to 30 seconds; c) 30 up-to 45 seconds;
and d) 45 up-to 60 seconds. The gray regions between two vertical lines indicate the start of
the events up-to the end of the longest events in each group. The total number of averaged
apneas for each subfigure is included at the top right. The peaks and drops representative
for the mean apnea hemodynamics response to obstructive apneic events for each group are
labeled. See Figure 1-a for the visualization of the di erent apneas grouped by their duration
before averaging.
Figure 5: a) Mean change of arterial oxygen saturation ( SpO2), b) heart rate ( rHR), and
c) cerebral blood flow ( rCBF), for apnea durations from 15 up-to 30 seconds. The gray
regions between two vertical lines indicate the start of the events up-to the end of the longest
events of 30 seconds. The total number of averaged apneas for each subfigure is included at
the top right. The peaks and drops representative for the mean  SpO2,  rHR and  rCBF
response to obstructive apneic events are labeled. See Figure 1-a for the visualization of the
di erent apneas grouped by their duration before averaging.
Figure 6: Mean relative cerebral blood flow ( rCBF) of apneas longer than 15 and up-to
30 seconds. a) Average of all obstructive events, b) those with no previous event 20 seconds
before, c) 30 seconds before, d) 40 seconds before and e) 50 seconds before. The gray regions
between two vertical lines indicates the start of the events up-to the end of the longest event
of 30 seconds. The total number of averaged apneas for each panel is included at the top
right.
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